TC Biopharm is a global leader in GD-T immunotherapy, developed on a unique proprietary technology platform. The company specialises using gamma delta GD-T cells as a treatment for cancer.

Existing T cell therapies have had billions of dollars invested, and are based on genetically modified alpha beta cells, called CAR-T, which are complex, expensive and have significant side effects. This technology has significant potential to improve patient health and quality of life.

Author: Clive Gunther